Nycomed’s purchase of ALTANA Pharma AG completed

29.12.2006

Nycomed and ALTANA AG have announced the closing of the transaction from the New Year transferring ALTANA Pharma AG to Nycomed.

At a closing ceremony in Frankfurt today, the formal transfer of shares from ALTANA AG to Nycomed was signed by representatives of both sides. The transfer will take effect as of 1 January 2007.

On 21 September 2006, Nycomed announced that it had reached an agreement to acquire ALTANA Pharma AG, the pharmaceutical business of German-based international pharmaceuticals and chemicals group, ALTANA AG.

On 14 December, Nycomed announced that the transaction had been approved by the competition authorities in EU and the US, and finally, on 19 December 2006, the deal was approved by the large majority of shareholders present at the ALTANA AG extraordinary general meeting.

“We are excited to have closed this transaction in order to begin the integration of the two companies. Together, we will form the combined business into an outstanding new healthcare company with increased market strength and greater access to new products”, said Håkan Björklund, Nycomed CEO.

The new company will be officially launched on 16 January 2007.


About Nycomed

The combined group will continue under the Nycomed corporate brand name and will be headquartered in Zurich, Switzerland. ALTANA Pharma legal entities will keep their current company names until a change-over planned for later in 2007.

Based on 2005 results, the company will have an initial workforce of around 12,000 people across more than 40 countries, and have estimated annual sales of approximately € 3.1 billion and EBITDA of approximately € 848 million.

For more information visit http://www.nycomed.com/


For further information

Håkan Björklund, CEO
Phone +45 46 77 11 11

Christoffer Jensen, VP Communications
Phone +45 46 77 11 12
Mobile +45 22 43 69 44


 

 

For further information

Media:
General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Investors:
Christian B. Seidelin,

phone: +41 44 555 11 04

Related information


English PDF
Danish PDF

Top of page

Takeda Pharma